For reference: VendorInvestigate · ecnoglutide.
I want a method I can write down and repeat, not a rule of thumb.
I would rather over-engineer this than discover a problem later, within reason.
So: what is the actual procedure, and which steps matter as opposed to being ritual?
Mechanically, thermal history during shipping is different for every vial, so a lot that experienced thermal abuse may have internal variation even if it was originally homogeneous.
Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.
The part that matters: if the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.
Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.
The caveat is that sampling is a trade-off between cost and confidence, and neither test nor assumption is cost-free.
Assume segregation is possible, and design your sampling to catch it if it exists.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemStart from the question: how many vials from this lot do I need to test to claim that the lot meets specification, and the answer depends on both the lot size and the acceptable risk.
Stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.
The underlying point is that if the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.
Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.
Worth noting that thermal excursions during shipping affect different vials differently, so the lot may not be homogeneous even if it left the factory that way.
If testing multiple vials, state how many you tested and why you chose those vials.
edited 20 Mar 2026 by bac_or_bust — reworded for clarity after a comment
Worth being precise here: sampling plans exist precisely because testing everything is expensive, and they define the statistical relationship between sample size and lot-wide inference.
The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.
Under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.
One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.
The practical summary: a lot number without a sampling statement is a lot number without meaning.
Most suppliers test one vial per lot and report the result as lot homogeneity, which is sampling one item from one lot and extrapolating wildly.
Acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.
Assume segregation is possible, and design your sampling to catch it if it exists.
Specifically, the honest statement is that unless you have tested multiple vials or have segregation data, you are making an assumption about lot homogeneity that may not hold.
If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.
If testing multiple vials, state how many you tested and why you chose those vials.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.